Drug or treatment

Serplulimab clinical trials

• 39Clinical trials
• 1New in 30 days
• 2Countries

Newest trials

All recruiting trials (39)

• NeoCSR-Omics: CAPOX and Serplulimab Before or After Short-Course RT in Locally Advanced Rectal Cancer

  This trial tests whether giving CAPOX chemotherapy with the PD-1 blocker serplulimab before or after short-course radiotherapy helps people with locally advanced rectal cancer achieve complete clinical or pathological responses.

  Recruiting Phase 2 Chongqing University Cancer Hospital · Chongqing, Chongqing Municipality · NCT07898865

• YL201 plus serplulimab vs the usual chemo combo as first treatment for extensive-stage small cell lung cancer

  This trial tests whether adding YL201 to serplulimab can improve outcomes compared with standard carboplatin and etoposide plus serplulimab in adults with treatment-naïve extensive-stage SCLC.

  Recruiting at 2 sites Phase 3 MediLink Therapeutics (Suzhou) Co., Ltd. · Guangzhou, Guangdong and 1 other locations · NCT07739758

• Low-dose carboplatin with nab-paclitaxel plus delayed serplulimab as first-line therapy for advanced squamous NSCLC

  This trial tests whether giving a low-dose carboplatin and nab-paclitaxel together, with serplulimab started after a delay, helps people with advanced squamous non-small cell lung cancer who have no known targetable gene mutations.

  Recruiting Phase 2 People's Hospital of Quzhou · Quzhou, Zhejiang · NCT07647094

• HIPEC-primed therapy with serplulimab plus SOX/XELOX for locally advanced gastric cancer

  This study tests a HIPEC-priming approach followed by PD-1 blocker–based chemotherapy to see if it helps people with locally advanced gastric cancer who have not yet spread.

  Recruiting Phase 2 Shanghai Changzheng Hospital · Shanghai · NCT07621484

• Serplulimab plus second-line chemo/targeted therapy for early-relapse colorectal cancer after adjuvant therapy

  This trial tests whether adding serplulimab to standard second-line chemotherapy plus targeted therapy helps people whose colorectal cancer came back early after adjuvant treatment.

  Recruiting Phase 2 Fudan University · Shanghai · NCT07604909

• Serplulimab Monotherapy in Elderly NSCLC Patients with High PD-L1 (≥50%)

  This study tests whether serplulimab alone can help older adults with NSCLC who have high PD-L1 levels (≥50%).

  Recruiting Phase 2 Tang-Du Hospital · Xi'an, Shannxi · NCT07596121

• Teniposide + cisplatin + serplulimab versus etoposide + cisplatin + serplulimab for extensive-stage small-cell lung cancer

  This study tests whether replacing etoposide with teniposide, while keeping cisplatin and serplulimab, works better for adults with extensive-stage small-cell lung cancer.

  Recruiting Phase 2 Sun Yat-sen University · Guangzhou, Guangdong · NCT07583511

• Trastuzumab plus serplulimab with chemotherapy for HER2-positive advanced biliary tract or urothelial cancer after prior therapy

  This study will test whether adding trastuzumab and serplulimab to chemotherapy helps people with HER2-positive unresectable or metastatic biliary tract cancer or urothelial carcinoma who have not responded to standard treatment.

  Recruiting Phase 2 China Medical University, China · Shenyang, Liaoning · NCT07506057

• Neoadjuvant chemoradiotherapy with serplulimab and nimotuzumab for resectable locally advanced esophageal squamous cell carcinoma

  This trial will try adding serplulimab and nimotuzumab to preoperative chemoradiotherapy to see if it improves surgical and pathological outcomes for adults with resectable locally advanced esophageal squamous cell carcinoma.

  Recruiting Phase 2 Tianjin Medical University Cancer Institute and Hospital · Tianjin, Tianjin Municipality · NCT07457528

• Serplulimab versus nivolumab with chemotherapy before surgery for resectable stage II–IIIA squamous lung cancer

  This study will test whether giving serplulimab plus chemotherapy before surgery works better than nivolumab plus chemotherapy in adults with resectable stage II–IIIA squamous non-small cell lung cancer.

  Recruiting Phase 2 Fudan University · Shanghai, Shanghai Municipality · NCT07398937

• Short-course radiotherapy plus CAPOX chemotherapy with serplulimab and bevacizumab for mid-low MSS rectal cancer

  This trial will try short-course radiotherapy followed by CAPOX chemotherapy together with serplulimab and bevacizumab before surgery in people with mid-low MSS locally advanced rectal cancer to see if it is safe and shrinks tumors.

  Recruiting Phase 2 First Affiliated Hospital of Wenzhou Medical University · Wenzhou, Zhejiang · NCT07347951

• Serplulimab with chemoradiotherapy, with or without extra chemotherapy, for locally advanced cervical cancer

  This trial tests whether adding induction and consolidation chemotherapy to serplulimab plus concurrent chemoradiotherapy helps women with untreated locally advanced cervical cancer stay cancer-free longer.

  Recruiting Phase 2 Tianjin Medical University Cancer Institute and Hospital · Tianjin, Tianjin Municipality · NCT07340489

• Pre-surgery serplulimab with weekly paclitaxel and carboplatin for triple-negative breast cancer

  This trial tests whether adding serplulimab to weekly paclitaxel and carboplatin before surgery helps people with triple-negative breast cancer respond better to treatment.

  Recruiting Phase 2 RenJi Hospital · Shanghai · NCT07283692

• HLX43 plus serplulimab before surgery for non-small cell lung cancer

  This study tests whether giving HLX43 together with serplulimab before surgery helps adults with stage II–IIIB non-small cell lung cancer who don't have targetable genetic mutations.

  Recruiting Phase 2 Shanghai Henlius Biotech · Shanghai · NCT07269782

• HLX43 with Serplulimab in advanced lung cancer

  This study tests whether HLX43 given with serplulimab can help adults with advanced NSCLC or SCLC who have had prior chemotherapy and immunotherapy.

  Recruiting at 10 sites Phase 2 Shanghai Henlius Biotech · Hefei, Anhui and 9 other locations · NCT07253142

• First-line sequential AG and mFOLFOX with serplulimab and bevacizumab versus AG alone for advanced pancreatic cancer

  This trial will test whether adding serplulimab and bevacizumab to sequential AG and mFOLFOX chemotherapy helps people with untreated advanced pancreatic cancer live longer than standard AG chemotherapy alone.

  Recruiting Phase 3 Zhejiang Cancer Hospital · Hangzhou, Zhejiang · NCT07235930

• Serplulimab with Induction Chemotherapy and Radiotherapy in Locally Advanced Nasopharyngeal Carcinoma

  This phase 3 trial tests whether giving serplulimab with induction chemotherapy and radiotherapy, then maintenance therapy, can help people with locally advanced nasopharyngeal cancer who respond well to initial chemotherapy.

  Recruiting Phase 3 Union Hospital, Tongji Medical College, Huazhong University of Science and Technology · Wuhan, Hubei · NCT07177443

• GnP plus serplulimab with stereotactic body radiation therapy for first-line locally advanced pancreatic cancer.

  This trial will test whether combining GnP chemotherapy, the immunotherapy serplulimab, and focused SBRT helps people aged 18–75 with untreated, locally advanced pancreatic ductal adenocarcinoma.

  Recruiting Phase 2 West China Hospital · Chengdu, Sichuan · NCT07101679

• Combining Serplulimab with Chemotherapy for Early-stage Small Cell Lung Cancer

  This study is testing if combining a new drug called serplulimab with chemotherapy can help people with early-stage small cell lung cancer before surgery.

  Recruiting Phase 2 Guangdong Provincial People's Hospital · Guangzhou, Guangdong · NCT06911606

• Serplulimab plus nab-paclitaxel and epirubicin for early HR+/HER2- breast cancer

  This Phase 2 study will test whether adding serplulimab to nab-paclitaxel and epirubicin before surgery helps shrink early-stage HR+/HER2- breast cancers in adults.

  Recruiting Phase 2 Henan Cancer Hospital · Zhengzhou, Henan · NCT06860529

• Short-course radiation plus CAPEOX chemotherapy and serplulimab for MSS/pMMR rectal cancer with limited metastases

  This trial will try combining short-course radiotherapy, CAPEOX chemotherapy, and the immunotherapy serplulimab to see if it helps people with MSS/pMMR rectal cancer who have a small number of metastases.

  Recruiting Phase 2 First Affiliated Hospital of Zhejiang University · Hangzhou, Zhejiang · NCT06850103

• Evaluating HLX43 with Serplulimab for Advanced Solid Tumors

  This study is testing a new combination of two cancer treatments, HLX43 and Serplulimab, to see if they can help people with advanced solid tumors feel better and improve their outcomes.

  Recruiting at 3 sites Phase 1/2 Shanghai Henlius Biotech · Hunan, Changsha and 2 other locations · NCT06848699

• Combining Serplulimab with Chemotherapy for Early-stage HR+/HER2- Breast Cancer

  This study is testing if adding a new drug called serplulimab to standard chemotherapy helps people with early-stage HR+/HER2- breast cancer have better outcomes before surgery.

  Recruiting Henan Cancer Hospital · Zhengzhou · NCT06781281

• Combining Serplulimab with Chemoradiotherapy for High-Risk Postoperative Cervical Cancer

  This study is testing if adding the immunotherapy drug Serplulimab to standard chemoradiotherapy can help women with high-risk cervical cancer feel better after surgery.

  Recruiting Phase 2 Tianjin Medical University Cancer Institute and Hospital · Tianjin, Tianjin Municipality · NCT06727617

• Short-term radiotherapy followed by chemotherapy for advanced rectal cancer

  This study is testing a new treatment plan that combines short-term radiation and chemotherapy to see if it helps people with advanced rectal cancer have no remaining tumor cells after surgery.

  Recruiting at 3 sites Phase 2 Union Hospital, Tongji Medical College, Huazhong University of Science and Technology · Wuhan, Hubei and 2 other locations · NCT06542588

• Combining Serplulimab with Targeted Therapy and Chemotherapy for Advanced Colorectal Cancer

  This study is testing if adding Serplulimab to targeted therapy and chemotherapy can help people with advanced colorectal cancer live longer and feel better.

  Recruiting Phase 2 Fudan University · Fuzhou, Fujian and 9 other locations · NCT06521866

• Maintenance lurbinectedin with serplulimab after first-line therapy for extensive-stage small cell lung cancer

  This study tests whether continuing lurbinectedin with serplulimab after initial treatment helps people with extensive-stage small cell lung cancer stay disease control.

  Recruiting Phase 2 Guangzhou Institute of Respiratory Disease · Guangzhou, Guangdong · NCT06497530

• Combining Bevacizumab and Serplulimab with a New Treatment for Malignant Ascites

  This study is testing a new treatment that combines two drugs with a special therapy to see if it can help people with severe abdominal fluid buildup from digestive system cancers who haven't found relief from other treatments.

  Recruiting at 3 sites Phase 2 Sun Yat-sen University · Guangzhou, Guangdong and 2 other locations · NCT06433869

• Combining Serplulimab with Chemoradiotherapy for Elderly Patients with Advanced Esophageal Cancer

  This study is testing if combining a new drug called Serplulimab with standard chemotherapy and radiation can help older patients with advanced esophageal cancer who can't have surgery feel better and live longer.

  Recruiting Phase 2 The First Affiliated Hospital with Nanjing Medical University · Nanjing, Jiangsu · NCT06354218

• Exploring dosage and effectiveness of HLX10 and HLX04 in liver cancer patients

  This study is testing different doses of two new treatments for liver cancer to see how well they work and if they are safe for patients who haven't had treatment before.

  Recruiting Phase 2 Shanghai Henlius Biotech · Shanghai · NCT06349980

• Combining Serplulimab and Bevacizumab with FOLFOX for Colorectal Cancer Treatment

  This study is testing if adding two new drugs to standard chemotherapy can help people with colorectal cancer that has spread to the liver live longer and have fewer chances of the cancer coming back after surgery.

  Recruiting Phase 2/3 Sun Yat-sen University · Guangzhou, Guangdong · NCT06280495

• Combining taurine with chemotherapy and immunotherapy for advanced gastric cancer treatment

  This study is testing if adding taurine to chemotherapy and immunotherapy can help people with advanced gastric cancer feel better and improve their treatment results.

  Recruiting at 15 sites Tang-Du Hospital · Wuhan, Hubei and 14 other locations · NCT06128252

• Combining Serplulimab, Trastuzumab, and Chemotherapy for Her-2+ Gastric Cancer

  This study is testing if combining Serplulimab, Trastuzumab, and chemotherapy can help people with stage II-III Her2+ gastric cancer live longer after surgery.

  Recruiting Phase 2 Fudan University · Shanghai, Shanghai Municipality · NCT05975749

• Third-line fruquintinib plus serplulimab for advanced metastatic colorectal cancer without liver-only metastases

  This tests whether combining fruquintinib and serplulimab helps people with microsatellite-stable metastatic colorectal cancer who have already failed standard treatments.

  Recruiting Phase 2 Fudan University · Shanghai, Shanghai Municipality and 1 other locations · NCT05954429

• Combining chemotherapy with serplulimab for advanced gastric cancer

  This study is testing if adding a new drug called serplulimab to standard chemotherapy can help people with advanced stomach cancer do better than those who only get chemotherapy.

  Recruiting Phase 2 First Affiliated Hospital of Zhejiang University · Hangzhou, Zhejiang and 4 other locations · NCT05872685

• Evaluating Serplulimab with Chemotherapy for Lung Cancer Treatment

  This study is testing if adding Serplulimab to chemotherapy can help people with advanced lung cancer turn their tumors into ones that can be surgically removed and live longer without the cancer coming back.

  Recruiting Phase 2 Zhejiang University · Hangzhou, Zhejiang · NCT05837052

• Surufatinib and Serplulimab with Platinum/Etoposide for Neuroendocrine Carcinoma

  This study tests a combination of targeted therapy, immunotherapy, and chemotherapy in adults with newly treated neuroendocrine carcinoma to see if the regimen is safe and helps shrink tumors.

  Recruiting Phase 1/2 Union Hospital, Tongji Medical College, Huazhong University of Science and Technology · Wuhan, Hubei · NCT05747729

• Combining serplulimab with chemotherapy for treating colon cancer spread to the abdomen

  This study is testing if adding serplulimab to chemotherapy can help people with colon cancer that has spread to the abdomen feel better and live longer.

  Recruiting Phase 2 Second Affiliated Hospital, Zhejiang University, School of Medicine · Huzhou, Zhejiang · NCT05742425

• Evaluating a new treatment for metastatic colorectal cancer

  This study is testing a new treatment combining Serplulimab, Bevacizumab, and chemotherapy to see if it helps people with advanced colorectal cancer feel better and live longer.

  Recruiting at 4 sites Phase 2/3 Shanghai Henlius Biotech · Guangzhou, Guangdong and 4 other locations · NCT04547166

Quick answers

How many clinical trials of Serplulimab are recruiting right now?

39, as of November 12, 2026. 1 of them was first registered in the last 30 days. We update this list each time we refresh our data from ClinicalTrials.gov.

Where are these trials running?

In 2 countries. The most sites are in China (39 trials), Japan (1 trial). Each study page lists its sites and which ones are recruiting.

What phases are they in?

Phase 2: 30, Phase 3: 3, Phase 1/2: 2, Phase 2/3: 2. Trials with no phase listed are usually device, behavioural or observational studies.

How do I join one?

Open a study, check the "Is this trial a fit for you?" section, then contact the study team listed on the page. They will ask a few screening questions. Asking is free and does not commit you to anything. Talk it over with your doctor first.

Find the studies that fit you

A list is a starting point. Tell us your situation in your own words and we'll rank the studies that match and explain why. It's free and needs no account.

Describe your situation →